Arrowhead Pharmaceuticals reported positive top-line results from Phase 3 studies of plozasiran (Redemplo) in severe hypertriglyceridemia, setting up a supplemental NDA filing with the FDA before year-end. The company said the program met primary and prespecified secondary endpoints across the trials. The data reinforce Arrowhead’s strategy to expand Redemplo beyond its existing approval for familial chylomicronemia syndrome. In parallel, the results strengthen competitive positioning against Ionis’ triglyceride gene-silencing therapy. Investors will focus on the completeness of efficacy and safety characterization once detailed results are presented, including how the benefit translates across patient subgroups and how it aligns with FDA label expectations for severe hypertriglyceridemia.